Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

BUY
$0.23 - $1.74 $109 - $824
474 New
474 $0
Q4 2022

Feb 13, 2023

BUY
$2.85 - $5.18 $484 - $880
170 New
170 $0
Q2 2021

Aug 16, 2021

SELL
$12.89 - $16.58 $702,208 - $903,228
-54,477 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$14.0 - $20.72 $762,678 - $1.13 Million
54,477 New
54,477 $782,000
Q3 2020

Nov 12, 2020

SELL
$11.92 - $15.87 $1.59 Million - $2.11 Million
-133,254 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$7.53 - $14.93 $20.8 Million - $41.2 Million
-2,756,287 Reduced 95.39%
133,254 $1.94 Million
Q1 2020

May 13, 2020

BUY
$5.69 - $17.78 $3.44 Million - $10.8 Million
605,068 Added 26.49%
2,889,541 $24.6 Million
Q4 2019

Feb 14, 2020

BUY
$10.89 - $16.79 $640,408 - $987,369
58,807 Added 2.64%
2,284,473 $37.6 Million
Q3 2019

Nov 14, 2019

BUY
$12.03 - $19.94 $14.4 Million - $23.9 Million
1,197,159 Added 116.4%
2,225,666 $31.4 Million
Q2 2019

Aug 14, 2019

BUY
$19.05 - $41.04 $2.39 Million - $5.14 Million
125,200 Added 13.86%
1,028,507 $20.7 Million
Q1 2019

May 10, 2019

BUY
$28.4 - $41.74 $8.27 Million - $12.2 Million
291,207 Added 47.58%
903,307 $35.9 Million
Q4 2018

Feb 13, 2019

BUY
$30.9 - $42.97 $4.22 Million - $5.87 Million
136,700 Added 28.75%
612,100 $21.3 Million
Q2 2018

Aug 10, 2018

SELL
$35.15 - $51.45 $40,106 - $58,704
-1,141 Reduced 0.24%
475,400 $17.5 Million
Q1 2018

May 09, 2018

BUY
$18.0 - $48.35 $8.58 Million - $23 Million
476,541 New
476,541 $18.6 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.